- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
FDA grants HAE drug Ruconest 12-years of exclusivity
8 October 2015 • Author: Victoria White
Salix, a division of Valeant Pharmaceuticals, and Pharming have announced that the US Food and Drug Administration (FDA) has granted 12 years of exclusivity to Ruconest (C1 Esterase Inhibitor [Recombinant]), ensuring that the FDA will not approve any applications for biosimilars of the drug before 16 July 2026.
Ruconest was approved by the FDA in July last year for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema (HAE).
A rare condition occurring in about 1 in 10,000 to 1 in 50,000 people worldwide, HAE is potentially life-threatening and stems from a genetic defect that impacts the production of C1-INH protein. This can lead to a biochemical imbalance that causes swelling in various parts of the body, including the hands, feet and face. Swelling in the intestinal wall can also cause severe abdominal pain, nausea and vomiting. Due to its rarity, many patients often remain undiagnosed for years.
Commenting on the exclusivity, Deb Jorn, Executive Vice President/Company Group Chairman, Valeant Pharmaceuticals, said, “We are pleased the anticipated exclusivity for RUCONEST has been formally granted. The response to Ruconest has been positive since its launch in November 2014 and we look forward to continued growth.”
Sijmen de Vries, Pharming’s CEO, added, “Pharming strived to make Ruconest available to the HAE patient community in the US, because we were aware of the great value and benefits that Ruconest could provide to patients. That the FDA granted 12 year exclusivity for Ruconest reinforces this long-standing commitment and we are excited to continue to work closely with Salix to ensure patients in the US have access to Ruconest.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics